Clinical trial
A Randomized, Double-blind, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of LY01015 and Opdivo®（Nivolumab Injection）Combined Respectively With Fluorouracil Plus Cisplatin in Participants With Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
NCT06022861 is registered in ClinicalTrials.gov with Shandong Boan Biotechnology Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of LY01015 and Opdivo®（Nivolumab Injection）Combined Respectively With Fluorouracil Plus Cisplatin in Participants With Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
- Lead sponsor
- Shandong Boan Biotechnology Co., Ltd
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- October 12, 2023
- Completion date
- October 30, 2026
- Enrollment
- 510 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.